Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and health care issues, forecasts sales of gastrointestinal drugs will reach $11.7 billion in 2007. According to the new DR Pipeline Report entitled Pipeline Analysis of Key Players in the Gastrointestinal Disease Market, Biogen, Celltech Group, Forest Laboratories, and Solvay Pharmaceuticals are all attempting to break into the market long dominated by AstraZeneca and TAP Pharmaceuticals.

(Photo: http://www.newscom.com/cgi-bin/prnh/20030626/DECLOGO )

"AstraZeneca and TAP Pharmaceuticals will account for approximately half of all gastrointestinal disease drug sales," said Michael Ryan, analyst at Decision Resources. "Markets for inflammatory bowel disease, irritable bowel syndrome and gastroesophageal reflux disease therapies are highly fragmented and permeated with generics, so attaining even a 1% market share by 2007 would be a significant achievement for emerging players like Biogen, Celltech Group, Forrest Laboratories and Solvay Pharmaceuticals."

Biogen is an example of a struggling emerging player in the gastrointestinal drug market. The company may attain a presence in the irritable bowel disease market with natalizumab, a humanized monoclonal antibody co-developed with Elan, in Phase III trials for Crohn's disease (CD). In July 2003, Biogen and Elan announced that natalizumab had failed to meet its primary endpoint of response in its Phase III induction trial; however, the companies believe these results to be due to a higher than expected placebo response rate. The maintenance trial in CD is ongoing, with results expected by the end of second quarter 2004.

About Gastrointestinal Diseases

Gastronintestinal diseases include inflammatory bowel disease (Crohn's disease and ulcerative colitis), irritable bowel syndrome, and gastroesophageal reflux disease. Gastronintestinal disorders significantly affect quality of life and are often misdiagnosed or undiagnosed. Because the etiology of these disorders is not well established, treatment has historically focused on symptom relief.

About DR Pipeline Reports from Decision Resources

DR Pipeline Reports are a series of comprehensive reports that focus on pharmaceutical and biotech company drug development and commercialization strategies. The 2003 Pipeline series reveals which compounds are most clinically effective and commercially viable within five therapeutic markets: major metabolic diseases, psychiatric disorders, gastrointestinal diseases, respiratory diseases, and viral infections.

About Decision Resources

Decision Resources is a world leader in research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. The company has provided strategic information services for more than 30 years, and assesses international pharmaceutical and health care industry trends. Visit Decision Resources at www.DecisionResources.com.

  For more information, contact:    Elizabeth Marshall    Decision Resources, Inc.    781-296-2563    emarshall@dresources.com 

Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20030626/DECLOGO
AP Archive: http://photoarchive.ap.org/
PRN Photo Desk, 888-776-6555 or 212-782-2840

SOURCE: Decision Resources, Inc.

CONTACT: Elizabeth Marshall of Decision Resources, Inc., +1-781-296-2563,
emarshall@dresources.com

Public Concern About Drug Addiction Constraining the Chronic Low Back Pain Market

View Now